Singapore markets closed

ACADIA Pharmaceuticals Inc. (0A4W.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
14.82-0.29 (-1.91%)
At close: 06:59PM BST

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871

Full-time employees610

Key executives

NameTitlePayExercisedYear born
Mr. Stephen R. Davis J.D.President, CEO & Director1.77M927.35k1961
Mr. Mark C. SchneyerExecutive VP & CFO821.81kN/A1974
Mr. Brendan P. TeehanExecutive VP, COO & Head of Commercial849.2kN/A1969
Mr. James K. KiharaVP, Chief Accounting Officer & Corporate ControllerN/AN/A1981
Dr. Elizabeth H.Z. Thompson Ph.D.Executive VP and Head of Research & DevelopmentN/AN/A1975
Mr. Benir RuanoSenior Vice President of Technical Development & OperationsN/AN/AN/A
Mr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Jennifer J. Rhodes J.D.Executive VP, Chief Legal Officer & SecretaryN/AN/A1970
Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyN/AN/AN/A
Ms. Holly ValdiviezSenior VP & Head of SalesN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Corporate governance

ACADIA Pharmaceuticals Inc.’s ISS governance QualityScore as of 1 June 2024 is 6. The pillar scores are Audit: 7; Board: 4; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.